Robert L. Taber, PhD
Robert L. Taber, PhD, is vice chancellor for corporate and venture development at Duke University.
Taber oversees patents and licenses for the entire university, commercially sponsored research, new venture activity, corporate gifts, and selected corporate vending relationships for this almost $2-billion enterprise.
Taber obtained his PhD degree in cell biology from the University of Pittsburgh School of Medicine in 1969 and went on to complete a post-doctoral fellowship at Massachusetts Institute of Technology. He subsequently served on the faculty of the University of Massachusetts School of Medicine, Roswell Park Memorial Institute, and the University of California at San Francisco School of Medicine. During this time, he also served as associate director of the Northern California Cancer Program based at Stanford University.
Taber left academics in 1981 to participate in the founding of Integrated Genetics Inc., where he became vice president of corporate development. The company went public in 1983 and was later acquired by Genzyme.
In 1985 Taber became president and CEO of EG&G MRI, a division of EG&G a $3-billion provider of services to the U.S. government and commercial businesses. His division performed biomedical testing for the biotechnology industry, National Institutes of Health, and the U.S. military.
In 1990 he participated in the founding of One Cell Systems, an analytic device company based on MIT technology, and became the company’s president and CEO. He left there in late 1992 to assume his current position at Duke.
Section Navigation
